Trial Endpoints for Candidemia and Invasive Candidiasis: Consensus Recommendations by the Mycoses Study Group Education & Research Consortium and European Confederation of Medical Mycology

Invasive candidiasis (IC) remains the most common invasive mycosis world-wide, responsible for a wide range of infections that can range from superficial mucosal infections to life-threatening systemic diseases. Clinical trials of antifungal agents for IC are pivotal to its management. Therapeutic responses in these trials are currently based on consensus criteria initially presented by the Mycoses Study Group (MSG) and the European Organization for Research and the Treatment of Cancer (EORTC) in 2008. These 2008 definitions originally described by Segal et al are still employed by both investigators and regulatory agencies when evaluating antifungal drug efficacy and patient outcomes. However, advances in clinical mycology, the change in epidemiology of Candida infections due to the increase in non-albicans Candida species, and the increase in newer antifungal agents currently under development require a revision of these criteria to ensure appropriate and standardized adjudication of patient outcomes and to accurately capture responses to newer therapeutic regimens and modern interventions. Therefore, the European Confederation of Medical Mycology (ECMM) and Mycoses Study Group Education and Research Consortium (MSGERC) have decided to revise the criteria to be used for future studies.

Authors

Institutions

Publication Details

Journal
Clinical Infectious Diseases
Published
2026-11-17
DOI
https://doi.org/10.1093/cid/ciag583
Citations
1
Primary Topic
Antifungal resistance and susceptibility
Type
article
Field-Weighted Citation Impact
3.05

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Trial Endpoints for Candidemia and Invasive Candidiasis: Consensus Recommendations by the Mycoses Study Group Education & Research Consortium and European Confederation of Medical Mycology

Indira Berrío, Thomas J. Walsh, Anuradha Chowdhary, Andreas H. Groll et al.
1 citations
Clinical Infectious Diseases
Antifungal resistance and susceptibility
3.05
article

Trial Endpoints for Candidemia and Invasive Candidiasis: Consensus Recommendations by the Mycoses Study Group Education & Research Consortium and European Confederation of Medical Mycology

Indira Berrío, Thomas J. Walsh, Anuradha Chowdhary, Andreas H. Groll, Julie M. Steinbrink, Shmuel Shoham, Sevtap Arıkan-Akdağlı, Martin Hoenigl, George R. Thompson, Sharon C.‐A. Chen, Patricia Muñóz, John W. Baddley, Juergen Prattes, José A. Vázquez
article en
1 citations

Abstract

Invasive candidiasis (IC) remains the most common invasive mycosis world-wide, responsible for a wide range of infections that can range from superficial mucosal infections to life-threatening systemic diseases. Clinical trials of antifungal agents for IC are pivotal to its management. Therapeutic responses in these trials are currently based on consensus criteria initially presented by the Mycoses Study Group (MSG) and the European Organization for Research and the Treatment of Cancer (EORTC) in 2008. These 2008 definitions originally described by Segal et al are still employed by both investigators and regulatory agencies when evaluating antifungal drug efficacy and patient outcomes. However, advances in clinical mycology, the change in epidemiology of Candida infections due to the increase in non-albicans Candida species, and the increase in newer antifungal agents currently under development require a revision of these criteria to ensure appropriate and standardized adjudication of patient outcomes and to accurately capture responses to newer therapeutic regimens and modern interventions. Therefore, the European Confederation of Medical Mycology (ECMM) and Mycoses Study Group Education and Research Consortium (MSGERC) have decided to revise the criteria to be used for future studies.

Clinical Infectious Diseases
University of Delhi (IN), Universidad Complutense de Madrid (ES), University of Maryland, Baltimore (US), Johns Hopkins University (US), Duke University (US), Medical University of Graz (AT), University of Münster (DE), Augusta University (US), Johns Hopkins Medicine (US), Westmead Hospital (AU), Hospital General Universitario Gregorio Marañón (ES), University of California San Diego (US), Augusta University Health (US), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES), Municipality of Medellín (CO), University Hospital Münster (DE), Duke Medical Center (US), Corporación para Investigaciones Biológicas (CO), University of California Davis Medical Center (US), Instituto de Investigación Sanitaria Gregorio Marañón (ES), NSW Health Pathology (AU), Hacettepe University (TR), University of California, Davis (US)
European Medicines Agency, Centers for Disease Control and Prevention
Good health and well-being
Openalex Percentile: Top 17%
Antifungal resistance and susceptibility
3.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon